GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

SXTP · Jun 30, 2024

60 DEGREES PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001213900-24-068673General Corporate

Debt relative to revenueRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.debt_to_revenue

120.03% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-950.78% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

109.92% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

340.89% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

28.33% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-3351.75% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

2476.82% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

2202.63% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History11 statesHistory building

Dec 31, 20230/8 normalizedLevel 3 Mar 31, 20240/7 normalizedLevel 3 Jun 30, 20240/8 normalizedLevel 3 Sep 30, 20240/9 normalizedLevel 3 Dec 31, 20240/9 normalizedLevel 3 Mar 31, 20250/9 normalizedLevel 3 Jun 30, 20254/9 normalizedLevel 3 Sep 30, 20256/9 normalizedLevel 3 Dec 31, 20257/9 normalizedLevel 3 Mar 31, 20267/9 normalizedLevel 3 Jun 30, 20269/9 normalizedLevel 3

Period transition

What moved in the state?

Balance Sheet Leverage Decreased

Previous: 128.80%
Current: 120.03%
Delta: -8.77%

Cash Generation Increased

Previous: -979.23%
Current: -950.78%
Delta: 28.45%

Inventory Pressure Decreased

Previous: 373.83%
Current: 340.89%
Delta: -32.94%

Margin Decreased

Previous: 43.81%
Current: 28.33%
Delta: -15.48%

Profitability Decreased

Previous: -1143.42%
Current: -3351.75%
Delta: -2208.33%

R And D Intensity Increased

Previous: 289.52%
Current: 2476.82%
Delta: 2187.30%

Sbc Intensity Increased

Previous: 744.73%
Current: 2202.63%
Delta: 1457.90%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · SXTP Fundamental State →Transitioned To · SXTP Fundamental State →Transitioned To · SXTP BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · SXTP CASH_GENERATION_INCREASED →Transitioned To · SXTP INVENTORY_PRESSURE_DECREASED →Transitioned To · SXTP MARGIN_DECREASED →Transitioned To · SXTP PROFITABILITY_DECREASED →Transitioned To · SXTP R_AND_D_INTENSITY_INCREASED →Transitioned To · SXTP SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.